Finance Review Daily is tracking this developing story; finance review daily will provide updates as verified details become available.
Novartis faces Phase 3 trial clinical setback for its $12B Avidity acquisition drug in myotonic dystrophy type 1.
1.1537▼ 0.12%
As of 14/09/2026, 21:00:00
Finance Review Daily is tracking this development following a report from the original source. Further verified details were not immediately available.
Dieser Artikel wurde mit KI-Unterstützung erstellt und von einer Finances-Review-Redakteurin bearbeitet.